Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850615 | 0.89 | ALDH1A1 (0.55) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL5409389 | 0.88 | ALDH1A1 (0.48) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL2290546 | 0.82 | HSD17B10 (0.44) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL29399101 | 0.82 | HSD17B10 (0.44) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL29801033 | 0.82 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL3418047 | 0.82 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL31450268 | 0.81 | HSD17B10 (0.42) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| Benzene SCHEMBL1724439 | 0.81 | HSD17B10 (0.42) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL19810029 | 0.81 | ALDH1A1 (0.35) | ALDH1A1HSD17B10HIF1ACYP1B1KDM4E | |
| SCHEMBL31497107 | 0.78 | HPRT1 (0.52) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086727-A9 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086727-A9 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20170233356-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233356-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2017-08-17 | — | — | US | disclosed |
| US-9562026-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562026-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562026-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140275241-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-18 | — | — | US | disclosed |
| US-20140275241-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-18 | — | — | US | disclosed |
| US-7470290-B2 | Hydroscopic polymer gels for easier cleaning | THE CLOROX COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7183010-B2 | Organic light-emitting diode devices with improved operational stability | EASTMAN KODAK CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050245428-A1 | Hydroscopic polymer gels for easier cleaning | RODRIGUES KLIN A | 2005-11-03 | — | — | US | disclosed |
| US-20040076853-A1 | Organic light-emitting diode devices with improved operational stability | EASTMAN KODAK COMPANY | 2004-04-22 | — | — | US | disclosed |
| EP-0301907-B1 | NOVEL SUBSTITUTED ANTHRASTEROID DERIVATES, THEIR PRODUCTION AND USE | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4874898-A | ANTIANDROGENS | SHIONOGI AND CO., LTD. PATENT DEPARTMENT (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0301907-A1 | Novel substituted anthrasteroid derivates, their production and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275241-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | ALDH1A1 384/4885HSD17B10 1096/4885HIF1A 2443/4885 |
| US-20170233356-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | ALDH1A1 384/4885HSD17B10 1096/4885HIF1A 2443/4885 |
| US-10160738-B2 | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors | GABRA4, GABRA2, GABRA6 | ALDH1A1 384/4885HSD17B10 1096/4885HIF1A 2443/4885 |
| US-20180086727-A9 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA2, GABRA6 | ALDH1A1 384/4885HSD17B10 1096/4885HIF1A 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.